Agenda for 2nd Annual Microbiome Discovery & Development Congress

Oxford Global would like to invite you to attend the 2nd Annual Microbiome Discovery & Development Congress, to be held on the 7th – 8th June 2018 in Berlin, Germany.

 

Following on from the success of last year’s congress and in response to the recent swell of industry activity in this area, we will explore the hottest topics and most recent innovations in the ever-growing microbiome field.

 

Key topics to be covered include:

• Novel Strategies & Technologies for Microbiome Drug Discovery
  Including Small Molecule Drug Development, Phage-based technologies, Bioinformatics
• Commercialising Microbiome Therapeutics
  Including Regulatory Issues, Intellectual Property, Collaboration between Pharmaceutical and Biotech companies
• Therapeutic Potential of the Microbiome
  Including Inflammatory Conditions, the Gut-Brain Axis, Probiotics, Dermatology

 

Key Presentations Include:

• Targeting the Microbiome – Through a Regulatory Lens
  Colette Shortt, Regulatory Director, Global Franchise Organisation, J&J Consumer               
• Microbiome & Skin Aging, an Example of Dysbiosis
  Lionel Breton, Scientific Director, Advanced Research, L’Oreal
• Uncovering the Hidden Chemistry of the Microbiome
   Ross Youngs, Chief Executive Officer, Biosortia
• Translation Microbiome Science To Brain-Axis Therapeutics
   Patrice Garnier, Chief Executive Officer, AMAbiotics
• Functional Screening In Neurodegenerative Disorders
  Imke Mulder, Research Director, 4D Pharma

 

New for 2018! Do not miss out on our Day 1 Workshop to explore the challenges of commercialising microbiome therapeutics, featuring:

• Colette Shortt, Regulatory Director, Global Franchise Organisation, J&J Consumer

Sanja Selak, Chief Executive Officer, Origimm

 

VIEW AGENDA:  http://bit.ly/2BOsODK